Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2373-2378

  Das, Sushmita ^a   Rani, Mukta ^a   Pandey, Krishna ^a   Sahoo, Ganesh Chandra ^a   Rabidas, Vidya Nand ^a   Singh, Dharmendra ^a   Das, Pradeep ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Combination therapy; Nitric oxide; TLR4 drug interaction; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MILTEFOSINE; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; PAROMOMYCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL TISSUE; ANTILEISHMANIAL IMMUNE RESPONSE; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; MALE; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; ARTIFICIAL GENE FUSION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; GENES, REPORTER; HUMANS; IMMUNOLOGIC FACTORS; LEISHMANIA DONOVANI; LUCIFERASES; MACROPHAGES; MALE; NF-KAPPA B; NITRIC OXIDE; PAROMOMYCIN; PHOSPHORYLCHOLINE; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866599760     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks220     Document Type: Article

References (10)

1. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-82.
2. Sundar S, Jha TK, Thakur CP et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-81.
3. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
4. Sundar S, Sinha PK, Rai M et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377: 477-86.
5. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
6. Sau K, Mambula SS, Latz E et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278: 37561-8.
7. Das S, Pandey K, Kumar A et al. TGF-b1 re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol 2011; doi:10.1038/icb.2011.80.
8. Seifert K, Escobar P, Croft SL. In vitro activity of antileishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 2010; 65: 508-11.
9. Matlashewski G, Arana B, Kroeger A et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis 2011; 11: 322-5.
10. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50: 73-9.